# Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

> **NCT01435018** · PHASE3 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 334 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Etoposide (ET)
- **DRUG:** Bleomycin and Vincristine (BV)
- **DRUG:** Paclitaxel (PTX)
- **DRUG:** Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)

## Key facts

- **NCT ID:** NCT01435018
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2018-03-13
- **Final completion:** 2019-08-29
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435018, "Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01435018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*